Clinical trial · Observational
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
A Large Scale, Multicenter, Real-World Study on Patients With Advanced GIST Receiving Ripretinib
NCT05697107CI-TRIAL-00063409unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ripretinib Oral Tablet | Drug | Ripretinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- approximately 7 months
- description
- To assess the efficacy (progression-free survival \[PFS\]
Secondary outcomes (2)
- measure
- DCR
- timeFrame
- approximately 6 months
- description
- To assess disease control rate (DCR)
- measure
- OS
- timeFrame
- approximately 12 months
- description
- to assess median overall survival (mOS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: -≥18 years old * Histologically confirmed gastrointestinal stromal tumor (GIST) * At least one measurable lesion (mRECIST v1.1) * Received or receiving ripretinib treatment Exclusion Criteria: * Patients who received \<1 cycle of ripretinib treatment * Medical records are incomplete
References
Publications (1)
- DERIVEDZhang X, Zhang P, Qiu H, Fang Y, Liu H, Zhou Y, Xu H, Yu J, Zhang J, Wang M, Shen L, Li J. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China. Adv Ther. 2023 Sep;40(9):3817-3829. doi: 10.1007/s12325-023-02576-0. Epub 2023 Jun 25. PMID 37356078